Elsevier

Clinics in Chest Medicine

Volume 17, Issue 4, 1 December 1996, Pages 697-711
Clinics in Chest Medicine

MYCOBACTERIAL COMPLICATIONS OF HIV INFECTION

https://doi.org/10.1016/S0272-5231(05)70340-3Get rights and content

Section snippets

FREQUENCY OF COEXISTING TUBERCULOSIS AND HIV INFECTION

At least four factors influence the rate of tuberculosis among HIV-infected populations: (1) the prevalence of latent infection with M. tuberculosis in the population; (2) the likelihood of exposure to persons with infectious tuberculosis; (3) the range of severity of immune compromise in the population and, thus, the likelihood of developing tuberculosis if infected with the organism; and (4) the frequency of use of isoniazid greatly reduces the risk for tuberculosis. These factors and perhaps

EFFECTS OF HIV INFECTION ON THE PATHOGENESIS OF TUBERCULOSIS

Tuberculosis develops by direct progression from recently acquired infection or by reactivation of latent infection. Because HIV impairs the ability to contain a new tuberculous infection, the risk of direct progression is much greater among persons with HIV infection; thus, an increasing number of cases may be occurring via this mechanism. Recent population-based studies of the molecular epidemiology of tuberculosis suggest that direct progression from infection to disease may be more common

Tuberculin Skin Testing and Anergy Testing

Because of the suppression of cell-mediated immunity, the tuberculin skin test commonly shows little or no reaction in persons with advanced HIV infection who also are infected with M. tuberculosis. In earlier stages of HIV infection, however, reactivity may be maintained. In a study reported by Markowitz and co-workers,92 the prevalence of positive (≥ 5-mm induration) tuberculin skin tests decreased progressively as the CD4+ cell count decreased, and the prevalence of anergy, as measured by

TREATMENT

Most reported series of patients with tuberculosis and HIV infection show a good response to antituberculosis treatment when regimens containing isoniazid and rifampin are used.10, 28, 116, 117, 118, 133, 139, 142 In a study from Zaire, the cure rate of a 6-month regimen was equal in HIV-infected and uninfected patients, but it was shown that administration of isoniazid plus rifampin for an additional 6 months was associated with a decreased rate of apparent relapse.113 Reinfection, however,

TUBERCULOSIS CAUSED BY MDR ORGANISMS

Explosive outbreaks of tuberculosis caused by MDR organisms (resistant to at least isoniazid and rifampin) have been reported.41, 44, 79 These outbreaks have taken place in hospitals and clinics and have predominantly involved HIV-infected patients.11 Health care workers, both HIV-seropositive and seronegative, have been infected. Substantial epidemiologic and laboratory DNA fingerprinting data indicate that transmission of the resistant M. tuberculosis has taken place in the health care

PREVENTION

The effectiveness of isoniazid preventive therapy in persons infected with HIV and M. tuberculosis was substantiated in a study conducted in Haiti by Pape and co-workers.110 In this study, administration of isoniazid, 300 mg/d for 12 months, significantly decreased the incidence of tuberculosis compared with placebo. Among newly identified HIV-infected persons who were without symptoms, rates of tuberculosis were 2.2 per 100 person-years for those given isoniazid compared with 7.5 per 100

NONTUBERCULOUS MYCOBACTERIAL DISEASES

Before the onset of the AIDS epidemic, disseminated nontuberculous mycobacterial disease was uncommon.70, 150 Between 1981 and 1987, more than 2000 cases of disseminated nontuberculous mycobacterial infections in HIV-infected patients were reported to the Centers for Disease Control and Prevention; 96% of these infections were due to MAC, another 2.9% were due to M. kansasii, and less than 1% were due to other nontuberculous mycobacteria.69 With improved survival because of the use of antiviral

Epidemiology

Disseminated MAC disease is the most common systemic bacterial infection in HIV-infected persons. In prospective cohort studies, 25% to 35% of all HIV-infected persons eventually developed disseminated MAC disease, making it the second most common opportunistic infection in this population.66, 76 The risk of disseminated MAC disease depends on the severity of cell-mediated immunodeficiency. In a prospective study, the 1-year actuarial incidence of MAC bacteremia was 3% among subjects with CD4+

OTHER NONTUBERCULOUS MYCOBACTERIA

Although nontuberculous mycobacteria other than MAC have been identified as causing infection in HIV-infected patients, their incidences have been relatively low, accounting for less than 4% of disseminated nontuberculous mycobacterial disease reported to the Centers for Disease Control and Prevention.69 Because of limited clinical experience with these organisms in HIV-infected patients, recommendations regarding management and treatment are primarily based on small series, anecdotal reports,

First page preview

First page preview
Click to open first page preview

References (156)

  • F. Kramer et al.

    Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection

    Am J Med

    (1990)
  • M.A. Montecalvo et al.

    Colonisation of potable water with Mycobacterium avium complex in homes of HIV-infected patients

    Lancet

    (1994)
  • E.A. Nardell

    Environmental control of tuberculosis

    Med Clin North Am

    (1993)
  • D. Alland et al.

    Transmission of tuberculosis in New York City: An analysis by DNA fingerprinting and conventional epidemiologic methods

    N Engl J Med

    (1994)
  • S. Allen et al.

    Prevalence of tuberculosis in HIV-infected urban Rwandan women

    Am Rev Respir Dis

    (1992)
  • American Thoracic Society/Centers for Disease Control and Prevention

    Treatment of tuberculosis and tuberculosis infection in adults and children

    Am J Respir Crit Care Med

    (1994)
  • American Thoracic Society

    Control of tuberculosis in the United States

    Am Rev Respir Dis

    (1992)
  • G. Antonucci et al.

    Risk factors for tuberculosis in HIV-infected persons: A prospective cohort study

    JAMA

    (1995)
  • V. Ausina et al.

    Mycobacterium xenopi infections in the acquired immunodeficiency syndrome

    Ann Intern Med

    (1988)
  • D. Barbaro et al.

    Mycobacterium avium-Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with AIDS

    Rev Infect Dis

    (1989)
  • P. Barnes et al.

    An unusual case of tuberculous peritonitis in a man with AIDS

    West J Med

    (1986)
  • J. Batungwanayo et al.

    Pulmonary tuberculosis in Kigali, Rwanda: Impact of human immunodeficiency virus infection on clinical and radiographic presentation

    Am Rev Respir Dis

    (1992)
  • C. Beck-Sague´ et al.

    Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections: Factors in transmission to staff and HIV-infected patients

    JAMA

    (1992)
  • Bergmann F, Schuermann D, Gruenewald T, et al: Frequency and clinical features of pulmonary infections with...
  • E. Bernard et al.

    Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.

    Antimicrob Agents Chemother

    (1993)
  • M. Bessesen et al.

    Disseminated Mycobacterium genavense infection: Clinical and microbiological features and response to therapy

    AIDS

    (1993)
  • E. Bishburg et al.

    Central nervous system tuberculosis with the acquired immunodeficiency syndrome and its related complex

    Ann Intern Med

    (1986)
  • D. Blumenthal et al.

    Mycobacterium avium complex-induced septic arthritis and osteomyelitis in a patient with the acquired immunodeficiency syndrome

    Arthritis Rheum

    (1990)
  • E. Bonnet et al.

    Clarithromycin: A potent agent against infections due to Mycobacterium marinum.

    Clin Infect Dis

    (1994)
  • E.C. Bo¨ttger

    Mycobacterium genavense: An emerging pathogen

    Eur J Clin Microbiol Infect Dis

    (1994)
  • J.M. Brody et al.

    Gastric tuberculosis: A manifestation of acquired immunodeficiency syndrome

    Radiology

    (1986)
  • K. Brudney et al.

    Resurgent tuberculosis in New York City

    Am Rev Respir Dis

    (1991)
  • M. Cappell et al.

    Gastrointestinal hemorrhage due to gastrointestinal Mycobacterium avium intracellulare or esophageal candidiasis in patients with the acquired immunodeficiency syndrome

    Am J Gastroenterol

    (1992)
  • J. Carpenter et al.

    Mycobacterium kansasii infections in patients positive for human immunodeficiency virus

    Rev Infect Dis

    (1991)
  • M. Cavicchi et al.

    Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase

    Clin Infect Dis

    (1995)
  • Centers for Disease Control and Prevention

    Tuberculosis and human immunodeficiency virus infection: Recommendation of the Advisory Committee for Elimination of Tuberculosis

    MMWR

    (1989)
  • Centers for Disease Control and Prevention

    USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus: A summary

    MMWR

    (1995)
  • R.E. Chaisson et al.

    Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

    Ann Intern Med

    (1994)
  • R.E. Chaisson et al.

    Tuberculosis in patients with the acquired immunodeficiency syndrome

    Am Rev Respir Dis

    (1987)
  • J. Chan et al.

    Mycobacterium gordonae in the acquired immunodeficiency syndrome

    Ann Intern Med

    (1984)
  • D.P. Chin et al.

    Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection

    J Infect Dis

    (1994)
  • D.P. Chin et al.

    Reliability of anergy skin testing in persons with HIV infection

    Am J Respir Crit Care Med

    (1996)
  • D.P. Chin et al.

    Predicting Mycobacterium avium complex bacteremia in patients infected with human immunodeficiency virus: A prospectively validated model

    Clin Infect Dis

    (1994)
  • K. Clouse et al.

    The HIV-1 gp 120 envelope protein has the intrinsic capacity to stimulate monokine secretion

    J Immunol

    (1991)
  • J. Cohen et al.

    Endophthalmitis due to Mycobacterium avium in a patient with AIDS

    Ann Ophthalmol

    (1990)
  • R.L. Colebunders et al.

    HIV infection in patients with tuberculosis in Kinshasa, Zaire

    Am Rev Respir Dis

    (1989)
  • C.L. Daley et al.

    An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus: An analysis using restriction-fragment-length polymorphisms

    N Engl J Med

    (1992)
  • K.M. De Cock et al.

    Tuberculosis and HIV infection in sub-saharan Africa

    JAMA

    (1992)
  • G. DiPerri et al.

    Nosocomial epidemic of active tuberculosis among HIV-infected patients

    Lancet

    (1989)
  • G. du Moulin et al.

    Concentration of Mycobacterium avium by hospital hot water systems

    JAMA

    (1988)
  • Cited by (0)

    Address reprint requests to Daniel P. Chin, MD, MPH, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, 1001 Potrero Avenue, Room 5K1, San Francisco, CA 94110

    View full text